nach oben

Current Bladder Dysfunction Reports

Erschienen in:

23.04.2019 | Voiding Dysfunction Evaluation (B Brucker and B Peyronnet, Section Editors)

Urinary Biomarkers and Benign Prostatic Hyperplasia

verfasst von: Pradeep Tyagi, Zhou Wang, Naoki Yoshimura

Erschienen in: Current Bladder Dysfunction Reports | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Benign prostatic hyperplasia (BPH) is a common age-related benign proliferation of the epithelial and stromal components of the prostate. Symptomatic BPH is associated with the progressive development of lower urinary tract symptoms (LUTS), which left untreated can deteriorate over time and lead to acute urinary retention, urinary incontinence, recurrent urinary tract infections, and/or obstructive uropathy.

Recent Findings

Surgical or medical treatment that correct bladder outlet obstruction from BPH in patients generally resolves voiding symptoms and reduces the urine levels of neurotrophins. Histological analysis of the prostate biopsies obtained from BPH patients enrolled in large clinical studies supported the role of prostatic inflammation in BPH/LUTS. However, the invasive nature of biopsy motivates the research in alternative biofluids for the discovery of biomarkers to influence the clinical management of BPH. We recently reported that urinary levels of chemokines are associated with the evidence of prostatic inflammation and measures of obesity in BPH patients.

Summary

Detection of inflammatory mediators in urine of BPH patients has the potential to displace biopsy for discriminating BPH-related pathologies, identify risk of progressive disease, and personalize the management of BPH-related LUTS.

• Yoo S, Oh S, Park J, Cho SY, Cho MC, Jeong H, et al. The impacts of metabolic syndrome and lifestyle on the prevalence of benign prostatic hyperplasia requiring treatment: historical cohort study of 130 454 men. BJU Int. 2018;123(1):140–8. https://doi.org/10.1111/bju.14528. Important epidemiological study demonstrating the influence of obesity on BPH. CrossRefPubMed

• Oelke M, Wagg A, Takita Y, Buttner H, Viktrup L. Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged ≥75 years: integrated analyses of pooled data from multinational, randomized, placebo-controlled clinical studies. BJU Int. 2017;119(5):793–803. https://doi.org/10.1111/bju.13744. Important study on the medical treatment of storage symptoms in BPH patients. CrossRefPubMed

• Vella M, Abrate A, Costanzo A, D'Amato F, Tarantino ML, Simonato A. Predictive variables of spontaneous micturition recovery after acute urinary retention in men with benign prostatic enlargement: an observational prospective study. Lower urinary tract symptoms. 2018. Doi:https://doi.org/10.1111/luts.12241. Important study identifying the predictors of treatment response.

•• Nickel JC, Roehrborn CG, Castro-Santamaria R, Freedland SJ, Moreira DM. Chronic prostate inflammation is associated with severity and progression of benign prostatic hyperplasia, lower urinary tract symptoms and risk of acute urinary retention. J Urol. 2016;196(5):1493–8. https://doi.org/10.1016/j.juro.2016.06.090. Important study implicating the role of prostatic inflammation in incidence of acute urinary retention and BPH/LUTS. CrossRefPubMed

Torkko KC, Wilson RS, Smith EE, Kusek JW, van Bokhoven A, Lucia MS. Prostate biopsy markers of inflammation are associated with risk of clinical progression of benign prostatic hyperplasia: findings from the MTOPS study. J Urol. 2015;194(2):454–61. https://doi.org/10.1016/j.juro.2015.03.103.CrossRefPubMed

• Matsukawa Y, Takai S, Majima T, Funahashi Y, Kato M, Yamamoto T, et al. Two-year follow up of silodosin on lower urinary tract functions and symptoms in patients with benign prostatic hyperplasia based on prostate size: a prospective investigation using urodynamics. Ther Adv Urol. 2018;10(9):263–72. https://doi.org/10.1177/1756287218783646. Important study on the influence of prostate size on treatment outcomes. CrossRefPubMedPubMedCentral

•• Young MJ, Elmussareh M, Morrison T, Wilson JR. The changing practice of transurethral resection of the prostate. Ann R Coll Surg Engl. 2018;100(4):326–9. https://doi.org/10.1308/rcsann.2018.0054. Important study demonstrating the benefits and shortcomings of TURP. CrossRefPubMedPubMedCentral

Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol. 2008;179(5 Suppl):S75–80. https://doi.org/10.1016/j.juro.2008.03.141.CrossRefPubMed

McNeal J, Noldus J. Limitations of transition zone needle biopsy findings in the prediction of transition zone cancer and tissue composition of benign nodular hyperplasia. Urology. 1996;48(5):751–6. https://doi.org/10.1016/S0090-4295(96)00254-3.CrossRefPubMed

10.

Descazeaud A, Rubin MA, Hofer M, Setlur S, Nikolaief N, Vacherot F, et al. BPH gene expression profile associated to prostate gland volume. Diagn Mol Pathol : the American journal of surgical pathology, part B. 2008;17(4):207–13. https://doi.org/10.1097/PDM.0b013e31816f6352.CrossRef

11.

Robert G, Descazeaud A, Nicolaiew N, Terry S, Sirab N, Vacherot F, et al. Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate. 2009;69(16):1774–80. https://doi.org/10.1002/pros.21027.CrossRefPubMedPubMedCentral

12.

• Hashimoto M, Shimizu N, Sugimoto K, Hongoh S, Minami T, Nozawa M, et al. Efficacy of adding dutasteride to alpha-blocker therapy treated benign prostatic hyperplasia patients with small volume prostate (<30 mL). Lower Urin Tract Symp. 2017;9(3):157–60. https://doi.org/10.1111/luts.12127. Important study on the influence of prostate size on treatment decision making. CrossRef

13.

Lin-Tsai O, Clark PE, Miller NL, Fowke JH, Hameed O, Hayward SW, et al. Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network. Prostate. 2014;74(6):669–79. https://doi.org/10.1002/pros.22785.CrossRefPubMedPubMedCentral

14.

Mullins C, Lucia MS, Hayward SW, Lee JY, Levitt JM, Lin VK, et al. A comprehensive approach toward novel serum biomarkers for benign prostatic hyperplasia: the MPSA consortium. J Urol. 2008;179(4):1243–56. https://doi.org/10.1016/j.juro.2007.11.049.CrossRefPubMedPubMedCentral

15.

Gumus BH, Nese N, Gunduz MI, Kandiloglu AR, Ceylan Y, Buyuksu C. Does asymptomatic inflammation increase PSA? A histopathological study comparing benign and malignant tissue biopsy specimens. Int Urol Nephrol. 2004;36(4):549–53.CrossRef

16.

Macoska JA. Chemokines and BPH/LUTS. Differentiation. 2011;82(4–5):253–60. https://doi.org/10.1016/j.diff.2011.04.003.CrossRefPubMedPubMedCentral

17.

Roehrborn CG. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin North Am. 2011;95(1):87–100. https://doi.org/10.1016/j.mcna.2010.08.013.CrossRefPubMed

18.

Liu L, Li Q, Han P, Li X, Zeng H, Zhu Y, et al. Evaluation of interleukin-8 in expressed prostatic secretion as a reliable biomarker of inflammation in benign prostatic hyperplasia. Urology. 2009;74(2):340–4. https://doi.org/10.1016/j.urology.2009.02.064.CrossRefPubMed

19.

Fujita K, Ewing CM, Getzenberg RH, Parsons JK, Isaacs WB, Pavlovich CP. Monocyte chemotactic protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia. Prostate. 2010;70(5):473–81. https://doi.org/10.1002/pros.21081.CrossRefPubMedPubMedCentral

20.

Desireddi NV, Campbell PL, Stern JA, Sobkoviak R, Chuai S, Shahrara S, et al. Monocyte chemoattractant protein-1 and macrophage inflammatory protein-1alpha as possible biomarkers for the chronic pelvic pain syndrome. J Urol. 2008;179(5):1857–61; discussion 61-2. https://doi.org/10.1016/j.juro.2008.01.028.CrossRefPubMedPubMedCentral

21.

Hu H, Zhang W, Liu X, Wang H, Fang Z, Liang C, et al. Nerve growth factor levels are associated with overactive bladder symptoms and long-term treatment outcome after transurethral resection of the prostate in patients with benign prostatic hyperplasia. J Urol. 2018;200(3):620–5. https://doi.org/10.1016/j.juro.2018.03.130.CrossRefPubMed

22.

•• Perez-Rambla C, Puchades-Carrasco L, Garcia-Flores M, Rubio-Briones J, Lopez-Guerrero JA, Pineda-Lucena A. Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia. Metabolomics. 2017;13(5):52. https://doi.org/10.1007/s11306-017-1194-y. Important study on the urine metabolomics approach in BPH. CrossRefPubMedPubMedCentral

23.

• Wang LW, Li JL, Yu Y, Xiao RH, Huang HW, Kuang RR, et al. Association of increased urine brain derived neurotrophic factor with lower urinary tract symptoms in men with benign prostatic hyperplasia. J Huazhong Univ Sci Technol Med Sci. 2017;37(4):531–5. https://doi.org/10.1007/s11596-017-1768-y. Important study linking urinary BDNF to LUTS. CrossRefPubMed

24.

Tanaka T, Minami A, Tashiro K, Yoshida N, Tohda A, Yamakoshi Y, et al. Urine miR-21-5p as a potential biomarker for predicting effectiveness of tadalafil in benign prostatic hyperplasia. Future Sci OA. 2018;4(6):FSO304. https://doi.org/10.4155/fsoa-2018-0012.CrossRefPubMedPubMedCentral

25.

• Tyagi P, Motley SS, Koyama T, Kashyap M, Gingrich J, Yoshimura N, et al. Molecular correlates in urine for the obesity and prostatic inflammation of BPH/LUTS patients. Prostate. 2018;78(1):17–24. https://doi.org/10.1002/pros.23439. Important study linking urinary sIL-1ra to obesity in BPH aptients. CrossRefPubMed

26.

• Tyagi P, Tyagi V, Qu X, Chuang YC, Kuo HC, Chancellor M, et al. Chemokines in urine noninvasively discriminate OAB from UTI. Am J Physiol Ren Physiol. 2016;311(3):F548–54. https://doi.org/10.1152/ajprenal.00213.2016. Important study illustrating differences in urinary chemokine levels in UTI and non-infective LUTS. CrossRef

27.

• Tyagi P, Killinger K, McLennan G, Jayabalan N, Chancellor M, Peters KM. Urine chemokine levels correlate with treatment response to phosphodiesterase 4 inhibitor in prostatitis. World J Clin Urol. 2017;6(1):18–26. Important study demonstrating the use of urinary chemokines to indicate treatment response. CrossRef

28.

Cho MC, Song WH, Park J, Cho SY, Jeong H, Oh SJ, et al. Long-term outcomes of laser prostatectomy for storage symptoms: comparison of serial 5-year followup data between high performance system photoselective vaporization and holmium laser enucleation of the prostate. J Urol. 2018;199(6):1591–9. https://doi.org/10.1016/j.juro.2018.01.022.CrossRefPubMed

29.

Barbosa J, Reis ST, Nunes M, Ferreira YA, Leite KR, Nahas WC, et al. The obstructed bladder: expression of collagen, matrix metalloproteinases, muscarinic receptors, and angiogenic and neurotrophic factors in patients with benign prostatic hyperplasia. Urology. 2017;106:167–72. https://doi.org/10.1016/j.urology.2017.05.010.CrossRefPubMed

30.

• Cho MC, Park J, Kim JK, Cho SY, Jeong H, Oh SJ, et al. Can preoperative detrusor underactivity influence surgical outcomes of 120 W HPS vaporization of the prostate (PVP) or holmium laser enucleation of the prostate (HoLEP)? A serial 3-year follow-up study. Neurourol Urodyn. 2018;37(1):407–16. https://doi.org/10.1002/nau.23317. Important study on surgical therapy for obstruction. CrossRefPubMed

31.

• Kashyap MP, Pore SK, de Groat WC, Chermansky CJ, Yoshimura N, Tyagi P. BDNF overexpression in the bladder induces neuronal changes to mediate bladder overactivity. Am J Physiol Ren Physiol. 2018;315(1):F45–56. https://doi.org/10.1152/ajprenal.00386.2017. Important study demonstrating the mechanistic link between urine BDNF levels and LUTS. CrossRef

32.

• Antunes-Lopes T, Vasconcelos A, Costa D, Charrua A, Neves J, Silva J, et al. The impact of chronic pelvic ischemia on LUTS and urinary levels of neuroinflammatory, inflammatory, and oxidative stress markers in elderly men: a case-control study. Urology. 2018;123:230–4. https://doi.org/10.1016/j.urology.2018.09.004. Important study demonstrating urine levels of different biomarkers. CrossRefPubMed

33.

• Ito H, Wang D, Zha X, Inamura S, Seki M, Taga M, et al. Castration increases PGE2 release from the bladder epithelium in male rats. Life Sci. 2018;193:252–6. https://doi.org/10.1016/j.lfs.2017.10.037. Important study demonstrating the changes in bladder wall in response to castration. CrossRefPubMed

34.

Chung BH, Roehrborn CG, Siami P, Major-Walker K, Morrill BB, Wilson TH, et al. Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH. Prostate Cancer Prostatic Dis. 2009;12(2):152–9. https://doi.org/10.1038/pcan.2008.49.CrossRefPubMed

35.

Di Carlo E, Magnasco S, D'Antuono T, Tenaglia R, Sorrentino C. The prostate-associated lymphoid tissue (PALT) is linked to the expression of homing chemokines CXCL13 and CCL21. Prostate. 2007;67(10):1070–80. https://doi.org/10.1002/pros.20604.CrossRefPubMed

36.

Steiner GE, Stix U, Handisurya A, Willheim M, Haitel A, Reithmayr F, et al. Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Investig. 2003;83(8):1131–46.CrossRef

37.

Nickel JC, True LD, Krieger JN, Berger RE, Boag AH, Young ID. Consensus development of a histopathological classification system for chronic prostatic inflammation. BJU Int. 2001;87(9):797–805.CrossRef

38.

De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schroder F, et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol. 2011;60(1):106–17. https://doi.org/10.1016/j.eururo.2011.03.055.CrossRefPubMed

39.

Theyer G, Kramer G, Assmann I, Sherwood E, Preinfalk W, Marberger M, et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Investig. 1992;66(1):96–107.PubMed

40.

•• Kulac I, Gumuskaya B, Drake CG, Gonzalez B, Arnold KB, Goodman PJ, et al. Peripheral zone inflammation is not strongly associated with lower urinary tract symptom incidence and progression in the placebo arm of the prostate cancer prevention trial. Prostate. 2016;76(15):1399–408. https://doi.org/10.1002/pros.23224. Important study demonstrating the effect on LUTS from inflammation in different zones of prostate. CrossRefPubMedPubMedCentral

41.

Roehrborn CG. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int. 2008;101(Suppl 3):17–21. https://doi.org/10.1111/j.1464-410X.2008.07497.x.CrossRefPubMed

42.

Moreira DM, Nickel JC, Gerber L, Muller RL, Andriole GL, Castro-Santamaria R, et al. Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study. Cancer. 2014;120(2):190–6. https://doi.org/10.1002/cncr.28349.CrossRefPubMed

43.

Roehrborn CG, Nickel JC, Andriole GL, Gagnier RP, Black L, Wilson TH, et al. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial. Urology. 2011;78(3):641–6. https://doi.org/10.1016/j.urology.2011.03.063.CrossRefPubMed

44.

Nickel JC, Roehrborn C, Montorsi F, Wilson TH, Rittmaster RS. Dutasteride reduces prostatitis symptoms compared with placebo in men enrolled in the REDUCE study. J Urol. 2011;186(4):1313–8. https://doi.org/10.1016/j.juro.2011.05.071.CrossRefPubMed

45.

St Sauver JL, Jacobson DJ, McGree ME, Lieber MM, Jacobsen SJ. Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia. Am J Epidemiol. 2006;164(8):760–8. https://doi.org/10.1093/aje/kwj258.CrossRefPubMed

46.

Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol. 2007;51(5):1202–16. https://doi.org/10.1016/j.eururo.2006.12.011.CrossRefPubMed

47.

Collin M, Linge HM, Bjartell A, Giwercman A, Malm J, Egesten A. Constitutive expression of the antibacterial CXC chemokine GCP-2/CXCL6 by epithelial cells of the male reproductive tract. J Reprod Immunol. 2008;79(1):37–43. https://doi.org/10.1016/j.jri.2008.08.003.CrossRefPubMed

48.

Linge HM, Collin M, Giwercman A, Malm J, Bjartell A, Egesten A. The antibacterial chemokine MIG/CXCL9 is constitutively expressed in epithelial cells of the male urogenital tract and is present in seminal plasma. J Interf Cytokine Res. 2008;28(3):191–6. https://doi.org/10.1089/jir.2007.0100.CrossRef

49.

Ao M, Franco OE, Park D, Raman D, Williams K, Hayward SW. Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res. 2007;67(9):4244–53. https://doi.org/10.1158/0008-5472.CAN-06-3946.CrossRefPubMed

50.

Perez de Lema G, Maier H, Nieto E, Vielhauer V, Luckow B, Mampaso F, et al. Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J Am Soc Nephrol. 2001;12(7):1369–82.PubMed

51.

Penna G, Fibbi B, Amuchastegui S, Cossetti C, Aquilano F, Laverny G, et al. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol. 2009;182(7):4056–64. https://doi.org/10.4049/jimmunol.0801875.CrossRefPubMed

52.

Penna G, Mondaini N, Amuchastegui S, Degli Innocenti S, Carini M, Giubilei G, et al. Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur Urol. 2007;51(2):524–33 discussion 33.CrossRef

53.

Mortier A, Van Damme J, Proost P. Regulation of chemokine activity by posttranslational modification. Pharmacol Ther. 2008;120(2):197–217. https://doi.org/10.1016/j.pharmthera.2008.08.006.CrossRefPubMed

54.

Macoska JA, Begley LA, Dunn RL, Siddiqui J, Wei JT, Sarma AV. Pilot and feasibility study of serum chemokines as markers to distinguish prostatic disease in men with low total serum PSA. Prostate. 2008;68(4):442–52. https://doi.org/10.1002/pros.20717.CrossRefPubMed

55.

Konig JE, Senge T, Allhoff EP, Konig W. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate. 2004;58(2):121–9. https://doi.org/10.1002/pros.10317.CrossRefPubMed

56.

Agarwal M, He C, Siddiqui J, Wei JT, Macoska JA. CCL11 (eotaxin-1): a new diagnostic serum marker for prostate cancer. Prostate. 2013;73(6):573–81. https://doi.org/10.1002/pros.22597.CrossRefPubMed

57.

Prakash K, Pirozzi G, Elashoff M, Munger W, Waga I, Dhir R, et al. Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays. Proc Natl Acad Sci U S A. 2002;99(11):7598–603. https://doi.org/10.1073/pnas.112191399.CrossRefPubMedPubMedCentral

58.

Gharaee-Kermani M, Kasina S, Moore BB, Thomas D, Mehra R, Macoska JA. CXC-type chemokines promote myofibroblast phenoconversion and prostatic fibrosis. PLoS One. 2012;7(11):e49278. https://doi.org/10.1371/journal.pone.0049278.CrossRefPubMedPubMedCentral

59.

Tyagi P, Motley SS, Kashyap M, Pore S, Gingrich J, Wang Z, et al. Urine chemokines indicate pathogenic association of obesity with BPH/LUTS. Int Urol Nephrol. 2015;47(7):1051–8. https://doi.org/10.1007/s11255-015-0992-2.CrossRefPubMedPubMedCentral

60.

Spary LK, Salimu J, Webber JP, Clayton A, Mason MD, Tabi Z. Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14 PD-L1 phenotype in prostate cancer. Oncoimmunology. 2014;3(9):e955331. https://doi.org/10.4161/21624011.2014.955331.CrossRefPubMedPubMedCentral

61.

Fan Y, Hu S, Liu J, Xiao F, Li X, Yu W, et al. Low intraprostatic DHT promotes the infiltration of CD8+ T cells in BPH tissues via modulation of CCL5 secretion. Mediat Inflamm. 2014;2014:397815–9. https://doi.org/10.1155/2014/397815.CrossRef

62.

Song L, Zhu Y, Han P, Chen N, Lin D, Lai J, et al. A retrospective study: correlation of histologic inflammation in biopsy specimens of Chinese men undergoing surgery for benign prostatic hyperplasia with serum prostate-specific antigen. Urology. 2011;77(3):688–92. https://doi.org/10.1016/j.urology.2010.07.493.CrossRefPubMed

63.

Morote J, Lopez M, Encabo G, de Torres IM. Effect of inflammation and benign prostatic enlargement on total and percent free serum prostatic specific antigen. Eur Urol. 2000;37(5):537–40.CrossRef

64.

Tyagi P, Barclay D, Zamora R, Yoshimura N, Peters K, Vodovotz Y, et al. Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study. Int Urol Nephrol. 2010;42(3):629–35. https://doi.org/10.1007/s11255-009-9647-5.CrossRefPubMed

65.

Motamedinia P, Scott AN, Bate KL, Sadeghi N, Salazar G, Shapiro E, et al. Urine exosomes for non-invasive assessment of gene expression and mutations of prostate cancer. PLoS One. 2016;11(5):e0154507. https://doi.org/10.1371/journal.pone.0154507.CrossRefPubMedPubMedCentral

66.

Bolduc S, Lacombe L, Naud A, Gregoire M, Fradet Y, Tremblay RR. Urinary PSA: A potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL. Can Urol Assoc J = Journal de l’Association des urologues du Canada. 2007;1(4):377–81.CrossRef

67.

Shibuya S, Xia Z, Sugimoto M, Ueda N, Haba R, Kakehi Y. The phytotherapeutic agent, eviprostat, suppresses stromal proliferation and inflammation even after establishment of nonbacterial prostatitis in the rat prostate. Urology. 2014;83(3):528–34. https://doi.org/10.1016/j.urology.2013.11.033.CrossRefPubMed

68.

Jia X, Chen J, Sun S, Yang W, Yang S, Shah P, et al. Detection of aggressive prostate cancer associated glycoproteins in urine using glycoproteomics and mass spectrometry. Proteomics. 2016;16(23):2989–96. https://doi.org/10.1002/pmic.201500506.CrossRefPubMedPubMedCentral

69.

Haraldsson B, Nystrom J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev. 2008;88(2):451–87. https://doi.org/10.1152/physrev.00055.2006.CrossRefPubMed

70.

Wada N, Matsumoto S, Kita M, Hashizume K, Kakizaki H. Decreased urinary nerve growth factor reflects prostatic volume reduction and relief of outlet obstruction in patients with benign prostatic enlargement treated with dutasteride. Int J Urol. 2014;21(12):1258–62. https://doi.org/10.1111/iju.12570.CrossRefPubMed

71.

Corcoran AT, Yoshimura N, Tyagi V, Jacobs B, Leng W, Tyagi P. Mapping the cytokine profile of painful bladder syndrome/interstitial cystitis in human bladder and urine specimens. World J Urol. 2013;31(1):241–6. https://doi.org/10.1007/s00345-012-0852-y.CrossRefPubMed

72.

Otoni A, Teixeira AL, Voieta I, Antunes CM, Costa Melo VL, Drummond SC, et al. Chemokine profile in the sera and urine of patients with schistosomal glomerulopathy. Am J Trop Med Hyg. 2014;90(1):48–53. https://doi.org/10.4269/ajtmh.13-0270.CrossRefPubMedPubMedCentral

73.

Kupelian V, Rosen RC, Roehrborn CG, Tyagi P, Chancellor MB, McKinlay JB. Association of overactive bladder and C-reactive protein levels. Results from the Boston Area Community Health (BACH) survey. BJU Int. 2012;110(3):401–7. https://doi.org/10.1111/j.1464-410X.2011.10769.x.CrossRefPubMed

74.

Tyagi P, Chancellor M, Kupelian V, Araujo A, Rosen R, McKinlay J. Obesity, inflammation and overactive bladder: preliminary results from a pilot study of serum leptin and mcp-1 levels in men and women with and without OAB symptoms. J Urol. 2011;185(4, Supplement):e462–e3. https://doi.org/10.1016/j.juro.2011.02.763.CrossRef

75.

Irani J, Goujon JM, Ragni E, Peyrat L, Hubert J, Saint F, et al. High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Pathol Multi Center Stud Group Urol. 1999;54(3):467–72.

76.

Kashyap M, Pore S, Wang Z, Gingrich J, Yoshimura N, Tyagi P. Inflammasomes are important mediators of prostatic inflammation associated with BPH. J Inflamm (Lond). 2015;12:37. https://doi.org/10.1186/s12950-015-0082-3.CrossRef

77.

Tyagi P, Kashyap M, Gingrich J, Wang Z, Yoshimura N. Mediators of prostatic inflammation: simultaneous multiplex analysis of urine and serum specimens. J Urol. 2017;197(4):161.CrossRef

78.

• Fowke JH, Koyama T, Fadare O, Clark PE. Does inflammation mediate the obesity and BPH relationship? An epidemiologic analysis of body composition and inflammatory markers in blood, urine, and prostate tissue, and the relationship with prostate enlargement and lower urinary tract symptoms. PLoS One. 2016;11(6):e0156918. https://doi.org/10.1371/journal.pone.0156918. Important study on serum analysis in BPH patients. CrossRefPubMedPubMedCentral

79.

Nobles C, Bertone-Johnson ER, Ronnenberg AG, Faraj JM, Zagarins S, Takashima-Uebelhoer BB, et al. Correlation of urine and plasma cytokine levels among reproductive-aged women. Eur J Clin Investig. 2015;45(5):460–5. https://doi.org/10.1111/eci.12428.CrossRef

80.

Vignozzi L, Rastrelli G, Corona G, Gacci M, Forti G, Maggi M. Benign prostatic hyperplasia: a new metabolic disease? J Endocrinol Investig. 2014;37(4):313–22. https://doi.org/10.1007/s40618-014-0051-3.CrossRef

81.

Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol. 2002;168(2):599–604.CrossRef

82.

Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev. 2002;13(4–5):323–40.CrossRef

83.

Kogan-Sakin I, Cohen M, Paland N, Madar S, Solomon H, Molchadsky A, et al. Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia-secreted IL-1. Carcinogenesis. 2009;30(4):698–705. https://doi.org/10.1093/carcin/bgp043.CrossRefPubMed

84.

Konwar R, Gara R, Singh M, Singh V, Chattopadhyay N, Bid HK. Association of interleukin-4 and interleukin-1 receptor antagonist gene polymorphisms and risk of benign prostatic hyperplasia. Urology. 2008;71(5):868–72. https://doi.org/10.1016/j.urology.2007.12.072.CrossRefPubMed

85.

Yadav DK, Tripathi AK, Gupta D, Shukla S, Singh AK, Kumar A, et al. Interleukin-1B (IL-1B-31 and IL-1B-511) and interleukin-1 receptor antagonist (IL-1Ra) gene polymorphisms in primary immune thrombocytopenia. Blood Res. 2017;52(4):264–9. https://doi.org/10.5045/br.2017.52.4.264.CrossRefPubMedPubMedCentral

86.

Rokita H, Kosz-Vnenchak M, Stalinska K, Stachura J. Interleukin 1 receptor antagonist localization exclusively in non-parenchymal cells of the mouse liver. Cytokine. 1997;9(4):249–53. https://doi.org/10.1006/cyto.1996.0161.CrossRefPubMed

87.

Giri D, Ittmann M. Interleukin-1alpha is a paracrine inducer of FGF7, a key epithelial growth factor in benign prostatic hyperplasia. Am J Pathol. 2000;157(1):249–55.CrossRef

88.

Vital P, Castro P, Tsang S, Ittmann M. The senescence-associated secretory phenotype promotes benign prostatic hyperplasia. Am J Pathol. 2014;184(3):721–31. https://doi.org/10.1016/j.ajpath.2013.11.015.CrossRefPubMedPubMedCentral

89.

Meier CA, Bobbioni E, Gabay C, Assimacopoulos-Jeannet F, Golay A, Dayer JM. IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin? J Clin Endocrinol Metab. 2002;87(3):1184–8. https://doi.org/10.1210/jcem.87.3.8351.CrossRefPubMed

90.

Charles BA, Doumatey A, Huang H, Zhou J, Chen G, Shriner D, et al. The roles of IL-6, IL-10, and IL-1RA in obesity and insulin resistance in African-Americans. J Clin Endocrinol Metab. 2011;96(12):E2018–22. https://doi.org/10.1210/jc.2011-1497.CrossRefPubMedPubMedCentral

91.

Bresnihan B, Cobby M. Clinical and radiological effects of anakinra in patients with rheumatoid arthritis. Rheumatology (Oxford). 2003;42(Suppl 2):ii22–8. https://doi.org/10.1093/rheumatology/keg329.CrossRef

92.

Rabbani F, Stroumbakis N, Kava BR, Cookson MS, Fair WR. Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol. 1998;159(4):1247–50.CrossRef

93.

Silva-Ramos M, Silva I, Oliveira JC, Correia-de-Sa P. Increased urinary adenosine triphosphate in patients with bladder outlet obstruction due to benign prostate hyperplasia. Prostate. 2016;76(15):1353–63. https://doi.org/10.1002/pros.23207.CrossRefPubMed

94.

Schauer IG, Ressler SJ, Tuxhorn JA, Dang TD, Rowley DR. Elevated epithelial expression of interleukin-8 correlates with myofibroblast reactive stroma in benign prostatic hyperplasia. Urology. 2008;72(1):205–13. https://doi.org/10.1016/j.urology.2007.11.083.CrossRefPubMedPubMedCentral

95.

Fontenete S, Silva J, Teixeira AL, Ribeiro R, Bastos E, Pina F, et al. Controversies in using urine samples for prostate cancer detection: PSA and PCA3 expression analysis. Int Braz J Urol : official journal of the Brazilian Society of Urology. 2011;37(6):719–26.CrossRef

96.

Mearini E, Antognelli C, Del Buono C, Cochetti G, Giannantoni A, Nardelli E, et al. The combination of urine DD3(PCA3) mRNA and PSA mRNA as molecular markers of prostate cancer. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals. 2009;14(4):235–43. https://doi.org/10.1080/13547500902807306.CrossRef

97.

Pejcic T, Hadzi-Djokic J, Markovic B, Dragicevic D, Glisic B, Lalic N, et al. Urinary PSA level and relative tumor volume after prostate biopsy. Acta Chirurgica Iugoslavica. 2009;56(2):17–21.CrossRef

98.

Veltri RW, Miller MC, Zhao G, Ng A, Marley GM, Wright GL Jr, et al. Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. Urology. 1999;53(1):139–47.CrossRef

99.

Reynard JM, Yang Q, Donovan JL, Peters TJ, Schafer W, de la Rosette JJ, et al. The ICS-‘BPH’ study: uroflowmetry, lower urinary tract symptoms and bladder outlet obstruction. Br J Urol. 1998;82(5):619–23.CrossRef

100.

Wu T, Fu Y, Brekken D, Yan M, Zhou XJ, Vanarsa K, et al. Urine proteome scans uncover total urinary protease, prostaglandin D synthase, serum amyloid P, and superoxide dismutase as potential markers of lupus nephritis. J Immunol. 2010;184(4):2183–93. https://doi.org/10.4049/jimmunol.0900292.CrossRefPubMedPubMedCentral

101.

Kamata Y, Kimura U, Matsuda H, Tengara S, Kamo A, Umehara Y, et al. Relationships among plasma granzyme B level, pruritus and dermatitis in patients with atopic dermatitis. J Dermatol Sci. 2016;84:266–71. https://doi.org/10.1016/j.jdermsci.2016.09.009.CrossRefPubMed

102.

Hung SF, Chung SD, Kuo HC. Increased serum C-reactive protein level is associated with increased storage lower urinary tract symptoms in men with benign prostatic hyperplasia. PLoS One. 2014;9(1):e85588. https://doi.org/10.1371/journal.pone.0085588.CrossRefPubMedPubMedCentral

103.

Jacobs BL, Smaldone MC, Tyagi V, Philips BJ, Jackman SV, Leng WW, et al. Increased nerve growth factor in neurogenic overactive bladder and interstitial cystitis patients. Can J Urol. 2010;17(1):4989–94.PubMed

104.

Tyagi P, Killinger K, Tyagi V, Nirmal J, Chancellor M, Peters KM. Urinary chemokines as noninvasive predictors of ulcerative interstitial cystitis. J Urol. 2012;187(6):2243–8. https://doi.org/10.1016/j.juro.2012.01.034.CrossRefPubMedPubMedCentral

Titel: Urinary Biomarkers and Benign Prostatic Hyperplasia
verfasst von: Pradeep Tyagi
Zhou Wang
Naoki Yoshimura
Publikationsdatum: 23.04.2019
Verlag: Springer US
Erschienen in: Current Bladder Dysfunction Reports / Ausgabe 2/2019
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI: https://doi.org/10.1007/s11884-019-00504-z

Neu im Fachgebiet Urologie

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Urinary Biomarkers and Benign Prostatic Hyperplasia

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Urologie

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Update Urologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

The WATER Study: a Review

Mathematical Modeling and Uroflow-Based Nomograms in Voiding Dysfunction Evaluation: Ready for Prime Time?

New Diagnostics for Male Lower Urinary Tract Symptoms

Primary and Secondary Tethered Cord and Association with Pediatric Lower Urinary Tract Dysfunction

Effects and Complications of Intravesical Instillation of Bacillus Calmette-Guerin Therapy

The Current Role of Botox in a Pediatric Neurogenic Bladder Condition

Neu im Fachgebiet Urologie

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Update Urologie